fda compounding semaglutide enforcement news november 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded GLP-1 Drugs and Telehealth Providers The FDA announced plans to

Dual and Triple Agonists: Molecules like tirzepatide (a GLP-1/GIP dual agonist) are just the beginning

Loomba, Rohit, et al

Acute pancreatitis was reported in the liraglutide group

Practitioners, like myself, who focus on reversing Hashimotos, often describe blood sugar imbalances as adding fuel to the fire in autoimmune thyroid disease

More serious but less common safety considerations observed across this drug class include a potential risk of pancreatitis, gallbladder-related conditions (such as gallstones/cholelithiasis), and based on animal studies a theoretical concern regarding thyroid C-cell tumours, though this has not been confirmed in human trials

As you lose weight and your metabolism stabilizes, your levothyroxine requirements may decrease